drugset
drugset / Trial / NCT04234594

Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

NCT04234594 ↗

Phase 1 Unknown 94 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind and parallel group study to compare the pharmacokinetic and safety of QL1203 and Vectibix® in healthy males.

Timeline

Start
2019-10-28
Primary completion
2020-09-30
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Panitumumab Monoclonal antibody 6 mg/kg Intravenous
Subject QL1203 Monoclonal antibody 6 mg/kg Intravenous

Indications

No indication recorded.